(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 45.79% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Syndax Pharmaceuticals's revenue in 2026 is $217,421,000.On average, 16 Wall Street analysts forecast SNDX's revenue for 2026 to be $30,962,115,634, with the lowest SNDX revenue forecast at $25,921,091,198, and the highest SNDX revenue forecast at $35,288,943,253. On average, 15 Wall Street analysts forecast SNDX's revenue for 2027 to be $44,162,351,357, with the lowest SNDX revenue forecast at $35,221,599,632, and the highest SNDX revenue forecast at $57,365,245,380.
In 2028, SNDX is forecast to generate $60,207,855,046 in revenue, with the lowest revenue forecast at $45,372,764,325 and the highest revenue forecast at $78,844,315,924.